View Past PerformanceThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsRite Aid バランスシートの健全性財務の健全性 基準チェック /06Rite Aidの総株主資本は$-2.0B 、総負債は$3.8Bで、負債比率は-191.6%となります。総資産と総負債はそれぞれ$7.1Bと$9.1Bです。主要情報-191.60%負債資本比率US$3.77b負債インタレスト・カバレッジ・レシオn/a現金US$97.12mエクイティ-US$1.97b負債合計US$9.09b総資産US$7.13b財務の健全性に関する最新情報お知らせ • Mar 30+ 4 more updatesMotion for Asset Sale Approved for Rite Aid CorporationThe US Bankruptcy Court gave an order approving the sale of the certain real property of Rite Aid Corporation on March 28, 2024. The debtor has been authorized to sell its certain assets to Moshe Faour, for a purchase price of $3.03 million. The debtor’s assets include Sale of Certain Real Property Located at 101 Main Street, Sayville, New York.お知らせ • Jan 13Rite Aid Corporation announced delayed 10-Q filingOn 01/12/2024, Rite Aid Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 18+ 4 more updatesNYSE Suspends Trading in Rite AidThe New York Stock Exchange LLC (“NYSE” or “Exchange”) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Rite Aid Corporation (the “Company”) — ticker symbol RAD — from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision that the Company’s common stock is no longer suitable for listing pursuant to Listed Company Manual Section 802.01D after the Company’s October 16, 2023 disclosure that the Company has filed voluntary petitions to commence proceedings under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of New Jersey. In reaching its delisting determination, NYSE Regulation noted that the restructuring term sheet contemplates that the Company’s equity holders are expected to receive no recovery. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the Company’s common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.お知らせ • Oct 17Rite Aid Corporation Filed for BankruptcyRite Aid Corporation, along with its 121 affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of New Jersey on October 15, 2023. The debtor listed both its assets and liabilities in the range of $1 billion to $10 billion. The debtor is represented by Michael D. Sirota of Cole Schotz P.C., Kirkland & Ellis LLP and Kirkland & Ellis International LLP as its legal counsels. The debtor also hired Guggenheim Partners as its investment banker, Alvarez & Marsal North America, LLC as its financial, tax, and restructuring advisor and Kroll Restructuring Administration as its notice and claims agent.お知らせ • Oct 13Rite Aid Corporation announced delayed 10-Q filingOn 10/12/2023, Rite Aid Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 05+ 1 more updateRite Aid Corporation Receives Written Notice from the New York Stock ExchangeOn September 28, 2023, Rite Aid Corporation received written notice from the New York Stock Exchange that the Company is no longer in compliance with NYSE continued listing standards set in Section 802.01B and Section 802.01C of the NYSE’s Listed Company Manual due to the fact that (i) the Company’s average total market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million; and (ii) the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period. As described in the Notice, as of September 27, 2023, (a) the Company’s 30 trading-day average market capitalization was approximately $49.97 million and its last reported stockholders’ deficit as of June 3, 2023, was approximately $(947.4) million; and (b) the 30 trading-day average closing price of the Company’s common stock was $0.88 per share. Pursuant to the NYSE rules, the Company has ten business days from receipt of the Notice to send a letter to the NYSE confirming receipt of the Notice and to indicate whether it intends to cure the deficiencies. If the Company determines to cure such deficiencies, the Company would then submit a business plan within 45 days of receipt of the Notice that demonstrates compliance with the Minimum Market Capitalization Standard within 18 months of receipt of the Notice. Upon receipt of such plan, the NYSE would have up to 45 days to review and determine whether the Company has made a reasonable demonstration of its ability to come into conformity with the relevant standards within the cure period. The NYSE may either accept the plan, at which time the Company would be subject to ongoing quarterly monitoring for compliance with the plan, or the NYSE may not accept the plan and the Company would be subject to suspension and delisting proceedings. The Company has six months from receipt of the Notice, or until the Company’s next annual meeting of stockholders if stockholder approval is required, to regain compliance with the Minimum Stock Price Standard by bringing its share price and 30 trading-day average share price above $1.00. Pursuant to the NYSE’s Minimum Stock Price Standard rules, the Company can regain compliance with the Minimum Stock Price Standard if, on the last trading day of any calendar month during the six-month cure period after its receipt of the Notice, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. In the event that, at the expiration of the six-month cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. Under the NYSE rules, the Company’s common stock will continue to be listed and traded on the NYSE during the independent cure periods outlined above, subject to the Company’s compliance with other continued listing requirements. The current noncompliance with the NYSE listing standards does not affect the Company’s ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements, nor does it trigger any violation of its material debt or other obligations. As previously disclosed by the Company, including in its Quarterly Report on Form 10-Q for the quarter ended June 3, 2023, filed with the U.S. Securities and Exchange Commission on July 11, 2023, the Company has been engaged in reviewing and continues to review strategic alternatives to recapitalize, refinance or otherwise optimize its capital structure, which may ultimately result in the Company pursuing one or more significant corporate transactions or other remedial measures. The Ongoing Review includes an evaluation of available options to regain compliance with the NYSE’s continued listing standards. The Company can provide no assurances that it will be able to satisfy any of the steps outlined above and maintain the listing of its shares on the NYSE or the results of the Ongoing Review.すべての更新を表示Recent updatesお知らせ • Sep 04Rite Aid Corporation Announces Resignation of Jeffrey S. Stein, as Chief Restructuring OfficerRite Aid Corporation announced Jeffrey S. Stein, who has stepped down as Chief Restructuring Officer in connection with the Company’s emergence from Chapter 11.お知らせ • Apr 05Rite Aid Announces Availability of Opill At All LocationsRite Aid Corporation announced Opill, the first daily oral contraceptive FDA-approved for purchase without a prescription, is now available in all stores. Opill is a progestin-only, daily oral contraceptive (birth control pill) that’s safe and effective when used as directed to help prevent pregnancy. Opill over-the-counter birth control pills are available at Rite Aid for the suggested retail price of $19.99 for a one-month supply and $49.99 for a three-month supply. Both options are available for purchase at Rite Aid stores nationwide and online at RiteAid.com. There are no restrictions for purchasing Opill. Rite Aid pharmacists are available to answer any customer questions about Opill.お知らせ • Mar 30+ 4 more updatesMotion for Asset Sale Approved for Rite Aid CorporationThe US Bankruptcy Court gave an order approving the sale of the certain real property of Rite Aid Corporation on March 28, 2024. The debtor has been authorized to sell its certain assets to Moshe Faour, for a purchase price of $3.03 million. The debtor’s assets include Sale of Certain Real Property Located at 101 Main Street, Sayville, New York.お知らせ • Jan 31Rite Aid Corporation (OTCPK:RADC.Q) acquired Tuttles Pharmacy Inc from Pellegrini family.Rite Aid Corporation (OTCPK:RADC.Q) acquired Tuttles Pharmacy Inc. from Pellegrini family on January 29, 2024.Rite Aid Corporation (OTCPK:RADC.Q) completed the acquisition of Tuttles Pharmacy Inc. from Pellegrini family on January 29, 2024.お知らせ • Jan 13Rite Aid Corporation announced delayed 10-Q filingOn 01/12/2024, Rite Aid Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 21Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Rite Aid Corporation Securities LitigationThe following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Rite Aid Securities Litigation: Investor purchased or acquired Rite Aid Corporation (Rite Aid) common stock between October 20, 2016 and June 28, 2017, inclusive (the “class”), investor could receive a payment from a class action settlement. Certain persons are excluded from the definition of the class as set forth in the stipulation of settlement. Pursuant to Rule 23 of the Federal Rules of Civil Procedure and by Order of the United States District Court for the Middle District of Pennsylvania, that in the above-captioned litigation (the “Action”), which is a certified class action, a Settlement has been proposed for $192,500,000.00 in cash. A hearing will be held on February 7, 2024, at 1:30 p.m., before the Honorable Jennifer P. Wilson, in Courtroom 8A, at the United States District Court for the Middle District of Pennsylvania, Sylvia H. Rambo U.S. Courthouse, 1501 North 6th Street, Harrisburg, PA 17102, for the purpose of determining whether: (1) the proposed Settlement should be approved by the Court as fair, reasonable, and adequate; (2) the proposed Plan of Allocation for distribution of the Settlement proceeds is fair, reasonable, and adequate and therefore should be approved; and (3) the application of Lead Counsel for the payment of attorneys’ fees and expenses from the Settlement Fund, including interest earned thereon, and requests by Plaintiffs for their time and expenses, should be approved.お知らせ • Oct 21Rite Aid Corporation Announces Board AppointmentsOn October 15, 2023, Rite Aid Corporation appointed Carrie Teffner and Paul Keglevic to the Company’s Board of Directors. Upon appointment, Mr. Keglevic and Ms. Teffner joined the Audit Committee of the Board, where Mr. Keglevic will serve as Chair. Ms. Teffner was also appointed as a member of the Compensation Committee of the Board. In connection with their respective appointments, Ms. Teffner and Mr. Keglevic will each be entitled to receive a cash directors’ fee equal to $50,000 per month, payable in arrears, and reimbursement for travel and lodging expenses associated with the directors’ services on the Board. Ms. Teffner has over 30 years of strategic, financial and operational leadership experience assisting retail and consumer product companies in driving growth and profitability. She has deep expertise leading successful large-scale transformation initiatives and has served as Executive Vice President and Chief Financial Officer at several Fortune 500 companies. Ms. Teffner currently serves on the boards of DXC Technology, International Data Group and BFA Industries. She previously served on the boards of Ascena Retail Group, Avaya and GameStop. Mr. Keglevic is an NACD-certified director with over 45 years of leadership experience and deep expertise in finance and accounting, operational improvement and turnarounds, restructuring and risk management across a range of industries. He has served as CEO, CFO, Chief Restructuring Officer and Chief Risk Officer at numerous companies, most recently as CEO of Energy Future Holdings. Earlier in his career, Mr. Keglevic was a Partner and member of the U.S. leadership team at PricewaterhouseCoopers. He currently serves on the boards of WeWork, Evergy and Envision Healthcare. Mr. Keglevic previously served on the boards of Ascena Retail Group, Bonanza Creek Energy, Clear Channel Holdings, Cobalt International Energy and Frontier Communications, among others. Prior to their respective appointments, Ms. Teffner and Mr. Keglevic, each entered into a letter agreement with the Company, dated as of July 5, 2023, pursuant to which Ms. Teffner and Mr. Keglevic provided consulting services to the Company on matters relating to refinancing, restructuring and deleveraging for the period between July 5, 2023 until their respective appointments on October 15, 2023. During such time, Ms. Teffner and Mr. Keglevic each received $200,000 in the aggregate, consisting of monthly fees payable by the Company pursuant to their respective letter agreements.お知らせ • Oct 20Rite Aid Corporation(OTCPK:RADC.Q) dropped from S&P TMI IndexRite Aid Corporation(OTCPK:RADC.Q) dropped from S&P TMI Indexお知らせ • Oct 19+ 1 more updateRite Aid Corporation(OTCPK:RADC.Q) dropped from S&P Global BMI IndexRite Aid Corporation(OTCPK:RADC.Q) dropped from S&P Global BMI Indexお知らせ • Oct 18+ 4 more updatesNYSE Suspends Trading in Rite AidThe New York Stock Exchange LLC (“NYSE” or “Exchange”) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Rite Aid Corporation (the “Company”) — ticker symbol RAD — from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision that the Company’s common stock is no longer suitable for listing pursuant to Listed Company Manual Section 802.01D after the Company’s October 16, 2023 disclosure that the Company has filed voluntary petitions to commence proceedings under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of New Jersey. In reaching its delisting determination, NYSE Regulation noted that the restructuring term sheet contemplates that the Company’s equity holders are expected to receive no recovery. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the Company’s common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.お知らせ • Oct 17Rite Aid Corporation Filed for BankruptcyRite Aid Corporation, along with its 121 affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of New Jersey on October 15, 2023. The debtor listed both its assets and liabilities in the range of $1 billion to $10 billion. The debtor is represented by Michael D. Sirota of Cole Schotz P.C., Kirkland & Ellis LLP and Kirkland & Ellis International LLP as its legal counsels. The debtor also hired Guggenheim Partners as its investment banker, Alvarez & Marsal North America, LLC as its financial, tax, and restructuring advisor and Kroll Restructuring Administration as its notice and claims agent.Seeking Alpha • Oct 16Rite Aid Shareholders Are Wiped Out Under A Chapter 11 Bankruptcy PlanSummary Rite Aid File for Ch.11 bankruptcy on October 15. Under the plan shareholders get no recovery and shares will be cancelled. There is a stalking horse bid of $575 million for Elixir. Secured noteholders get 100% of the new equity. McKesson is trying to terminate their supply contract with Rite Aid. Read the full article on Seeking Alphaお知らせ • Oct 13Rite Aid Corporation announced delayed 10-Q filingOn 10/12/2023, Rite Aid Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 05+ 1 more updateRite Aid Corporation Receives Written Notice from the New York Stock ExchangeOn September 28, 2023, Rite Aid Corporation received written notice from the New York Stock Exchange that the Company is no longer in compliance with NYSE continued listing standards set in Section 802.01B and Section 802.01C of the NYSE’s Listed Company Manual due to the fact that (i) the Company’s average total market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million; and (ii) the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period. As described in the Notice, as of September 27, 2023, (a) the Company’s 30 trading-day average market capitalization was approximately $49.97 million and its last reported stockholders’ deficit as of June 3, 2023, was approximately $(947.4) million; and (b) the 30 trading-day average closing price of the Company’s common stock was $0.88 per share. Pursuant to the NYSE rules, the Company has ten business days from receipt of the Notice to send a letter to the NYSE confirming receipt of the Notice and to indicate whether it intends to cure the deficiencies. If the Company determines to cure such deficiencies, the Company would then submit a business plan within 45 days of receipt of the Notice that demonstrates compliance with the Minimum Market Capitalization Standard within 18 months of receipt of the Notice. Upon receipt of such plan, the NYSE would have up to 45 days to review and determine whether the Company has made a reasonable demonstration of its ability to come into conformity with the relevant standards within the cure period. The NYSE may either accept the plan, at which time the Company would be subject to ongoing quarterly monitoring for compliance with the plan, or the NYSE may not accept the plan and the Company would be subject to suspension and delisting proceedings. The Company has six months from receipt of the Notice, or until the Company’s next annual meeting of stockholders if stockholder approval is required, to regain compliance with the Minimum Stock Price Standard by bringing its share price and 30 trading-day average share price above $1.00. Pursuant to the NYSE’s Minimum Stock Price Standard rules, the Company can regain compliance with the Minimum Stock Price Standard if, on the last trading day of any calendar month during the six-month cure period after its receipt of the Notice, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. In the event that, at the expiration of the six-month cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. Under the NYSE rules, the Company’s common stock will continue to be listed and traded on the NYSE during the independent cure periods outlined above, subject to the Company’s compliance with other continued listing requirements. The current noncompliance with the NYSE listing standards does not affect the Company’s ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements, nor does it trigger any violation of its material debt or other obligations. As previously disclosed by the Company, including in its Quarterly Report on Form 10-Q for the quarter ended June 3, 2023, filed with the U.S. Securities and Exchange Commission on July 11, 2023, the Company has been engaged in reviewing and continues to review strategic alternatives to recapitalize, refinance or otherwise optimize its capital structure, which may ultimately result in the Company pursuing one or more significant corporate transactions or other remedial measures. The Ongoing Review includes an evaluation of available options to regain compliance with the NYSE’s continued listing standards. The Company can provide no assurances that it will be able to satisfy any of the steps outlined above and maintain the listing of its shares on the NYSE or the results of the Ongoing Review.お知らせ • Sep 26Rite Aid Corporation is Heading Towards BankruptcyRite Aid Corporation is heading towards bankruptcy, as of September 22, 2023. Company is expected to file a Chapter 11 bankruptcy petition within the next couple of days as it nears an agreement with existing creditors. The company is finalizing a reorganization pact with its largest creditors/ is leading towards a bankruptcy proceeding under Chapter 11.お知らせ • Sep 16Rite Aid and Bartell Drugs Announce Availability of Appointments for Updated COVID-19 VaccineRite Aid announced that scheduling is now available for eligible customers seeking the updated COVID-19 (2023-2024) vaccines at its locations and at Bartell Drugs locations in the Pacific Northwest. Appointments are available beginning on September 22. The updated COVID-19 vaccine provides enhanced protection against currently circulating variants of COVID-19. The vaccine is recommended for individuals six months and older. An updated COVID-19 vaccine is needed for those who have not received a COVID-19 vaccine in the past two months, according to the CDC. Rite Aid pharmacists are trained to immunize customers ages three and older. Other immunizations, including the flu vaccine, can also be scheduled via the online scheduling tool. Both the COVID-19 and flu vaccinations can be administered during the same appointment.お知らせ • Sep 12Rite Aid Announces Availability of OTC NARCAN Nasal Spray At All LocationsRite Aid announced that NARCAN Nasal Spray, a medication used to reverse the effects of an opioid overdose, is available at all locations nationwide, including Bartell Drugs in the Pacific Northwest. NARCAN Nasal Spray can be purchased over the counter without a prescription. NARCAN Nasal spray (naloxone HCl 4 mg) is a medication designed to rapidly reverse the effects of a life-threatening opioid emergency and is the standard treatment for opioid overdose. It is now FDA-approved for OTC use and is available for purchase at Rite Aid stores nationwide and online at Rite Aid.com. Each carton of NARCAN Nasal Spray contains two single-dose devices. Each device contains one dose of medicine. The carton is readily available on shelves and at the pharmacy counter at Rite Aid stores and is priced at $45.99.お知らせ • Aug 05Rite Aid Corporation Announces Availability of Flu and RSV Vaccine Appointments at All LocationsRite Aid Corporation announced appointments for flu and RSV vaccines are available at all store locations, including Bartell Drugs in the Pacific Northwest. Customers can now schedule appointments to protect themselves and family members against the upcoming respiratory virus season through Rite Aid's online scheduler. Rite Aid will be offering flu vaccines protecting against the strains of influenza that are expected to circulate in the United States this year, as well as Flumist, a nasal spray flu vaccine, which is in limited supply at all locations. Customers receiving their flu shot will get a coupon for $5 off a $25 in-store purchase from now until Sept. 30, 2023. This offer excludes stores in New York or New Jersey and some restrictions apply. The Centers for Disease Control (CDC) recommends adults 60 years and older receive a single dose of RSV vaccine, based on discussions with their pharmacist or other healthcare provider. The RSV vaccine may be given at the same time as other vaccines. Rite Aid and Bartell Drugs also offer COVID-19 and other routine vaccinations at all locations, helping customers and families stay up to date on vaccines that provide critical protection against certain diseases, some of which are required for certain ages, activities or for overseas travel. Rite Aid and Bartell drugs will provide the new CDC-recommended COVID-19 vaccine once available, which will better protect against the most prevalent COVID-19 strain. Rite Aid pharmacists can provide additional guidance on which vaccines are right for each customer and advise on the timing of administration of each vaccine. To help customers assess their needs for routine immunizations, Rite Aid offers an Immunization Evaluation Questionnaire on its website. The questionnaire guides customers to ensure they are up to date with all necessary immunizations based on their age, conditions, or occupation. Rite Aid and Bartell's pharmacists can immunize adults and children three years of age and older against influenza. To schedule an appointment for a flu vaccine or other immunizations, Rite Aid customers can use the online scheduling tool at Rite Aid.com. Bartell Drugs customers can use the online scheduling tools linked here. All locations are currently accepting walk-ins. How online scheduling works: Using the online scheduling tool, customers may select a convenient time and location to schedule a vaccine appointment for flu, COVID-19 and other recommended vaccinations. Customers supply necessary information and consent forms securely online in advance of their appointment. Reminders will be sent in the days leading up to the appointment via customers' chosen communication preferences by text or email.New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$947m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$383m). Currently unprofitable and not forecast to become profitable over next 3 years (US$233m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change).お知らせ • Aug 02Rite Aid Corporation Announces Executive ChangesRite Aid Corporation announced that on July 28, 2023, Justin Mennen, the EVP and Chief Digital and Technology Officer of the Company, ceased to be employed by the Company, effective immediately.お知らせ • Jul 13Rite Aid Corporation, Annual General Meeting, Jul 26, 2023Rite Aid Corporation, Annual General Meeting, Jul 26, 2023.Seeking Alpha • Jul 10Rite Aid May Be Forced Into Ch.11 Bankruptcy To Resolve Opioid LiabilitiesSummary Rite Aid's stock is being downgraded from "Hold" to "Sell" due to the opioid lawsuit, ongoing financial losses, and ineffective management. Rite Aid reported a $(5.56) net loss per share for 1Q. Elixir will discontinue their Medicare Part D program for individuals starting next year. The stock is effectively trading at only about $0.08 after adjusting for the 1-20 reverse stock split a few years ago. Read the full article on Seeking AlphaMajor Estimate Revision • Jul 06Consensus EPS estimates fall by 52%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$21.8b to US$22.7b. Forecast EPS reduced from -US$8.23 to -US$12.50 per share. Consumer Retailing industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$1.50 to US$1.00. Share price fell 4.6% to US$1.46 over the past week.New Risk • Jul 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$947m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$383m). Currently unprofitable and not forecast to become profitable over next 2 years (US$292m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (US$83.4m market cap).お知らせ • Jun 30+ 2 more updatesRite Aid Corporation, Annual General Meeting, Aug 18, 2023Rite Aid Corporation, Annual General Meeting, Aug 18, 2023, at 11:30 US Eastern Standard Time. Agenda: To consider the Election of six directors to hold office until the 2024 Annual Meeting of Stockholders the Board's nominees; to consider Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm; to consider Advisory vote to approve the compensation of our named executive officers; to consider Advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers; to consider Approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions; to Consider and vote on a stockholder proposal to require an annual advisory vote on the compensation of Rite Aid's directors, if properly presented at the Annual Meeting; and to consider other business matters.Reported Earnings • Jun 29First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2024 results: US$5.56 loss per share (further deteriorated from US$2.03 loss in 1Q 2023). Revenue: US$5.65b (down 6.0% from 1Q 2023). Net loss: US$306.7m (loss widened 178% from 1Q 2023). Revenue exceeded analyst estimates by 8.1%. Earnings per share (EPS) missed analyst estimates by 130%. Revenue is expected to decline by 1.4% p.a. on average during the next 3 years, while revenues in the Consumer Retailing industry in the US are expected to grow by 4.2%. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.Seeking Alpha • Jun 27Rite Aid Q1 Earnings Preview: Bears Remain In ControlSummary Bears remain resolute in their strong bet against Rite Aid. Weak outlook from Walgreens hurt RAD stock ahead of the Q1 2024 report. Debt leverage and cost run rate remain a concern. Read the full article on Seeking Alphaお知らせ • Jun 25+ 1 more updateRite Aid Corporation(NYSE:RAD) dropped from Russell Small Cap Comp Growth IndexRite Aid Corporation(NYSE:RAD) dropped from Russell Small Cap Comp Growth Indexお知らせ • Jun 13Rite Aid Corporation to Report Q1, 2024 Results on Jun 29, 2023Rite Aid Corporation announced that they will report Q1, 2024 results on Jun 29, 2023お知らせ • Jun 10Rite Aid Corporation Names Thomas Sabatino Chief Legal OfficerRite Aid announced that Thomas Sabatino has joined the company as Executive Vice President and Chief Legal Officer. Sabatino will play a pivotal role in the company’s growth strategy to help create meaningful customer, client, and member experiences for millions of Americans. As Chief Legal Officer, he will oversee the organization’s legal affairs, including enterprise risk management, compliance, regulatory affairs, and privacy. Sabatino will become a member of the company's executive leadership team and report to Burr. He brings four decades of experience in the legal field navigating complex business needs. He was most recently the Executive Vice President and General Counsel at Tenneco Inc. His expertise runs deep in the healthcare industry with previous executive roles at Aetna, Walgreen Boots Alliance, Schering Plough Corp., and Baxter International Inc., where in each instance he was instrumental in driving large-scale growth and operational effectiveness. Sabatino currently serves as a member of the Board of Directors of the Humane Society of the United States and the South Florida Wildlife Center. He is Chair Emeritus of the International Institute for Conflict Prevention and Resolution and is on the Board of Advisors of the University of Pennsylvania Carey School of Law.お知らせ • Jun 06Rite Aid Announces Launch of RYSHI Beauty and Personal Care EssentialsRite Aid announced the launch of RYSHI™? - its exclusive collection of clean beauty and personal care essentials designed to let the real shine through. Spanning across multiple categories, RYSHI™? products offer better-for-you ingredients at an accessible price point so customers can conveniently build their beauty toolkit at their neighborhood Rite Aid. The full collection offers a vast range of products so customers can find answers to all their beauty and grooming needs under one trusted brand. From vegan lashes to hydrogel eye and sheet masks, to sunscreen, body wash, and razors, RYSHI™®? everyday essentials and self-pampering favorites are all priced under $20 to provide accessible, high-quality offerings to Rite Aid customers. To help customers embrace their true self and feel confident, radiant and clean, the RYSHI™? brand features a wide selection of products, including: Gua Shas/Facial Massagers, Facial Wipes, Hydrogel Eye Masks, Sheet Masks, Vegan Eye Lashes, Makeup Applicators, Eyelash Curlers, Hand Cream, Body Wash, Cotton Balls/Rounds, Sunscreen, Dry Brushes, Nail Care, Razors.Rite Aid created RYSHI™? with a commitment to clean and quality products. The collection is free from ingredients of concern such as parabens, perfluorinated substances (PFAS), triclosan, formaldehyde and formaldehyde releasers. In addition, all RYSHI™? product are independently lab tested to ensure product performance and safety and are backed by a 100% satisfaction guarantee. RYSHI™? will continue to expand its offerings through 2023, boasting more than 300 products--exclusively available at Rite Aid stores and on Rite Aid.com.お知らせ • May 24Elixir Announces the Next Wave of Innovation for Pharmacy Benefits Technology PlatformElixir has announced details of the next release of its Laker Software technology platform. The upcoming enhancements include new automated workflows, a customer service tool and modernization of the user interface. The upgrade will include a range of advanced functionalities that are designed to help customers better manage their pharmacy claims adjudication data and streamline workflows. The new features will allow users to access and share data more efficiently, collaborate more effectively, and improve productivity. Built on a resilient, scalable architecture, the Laker Software platform is a 100% virtualized environment. The platform processes millions of paid claims per year and is SOC 1 Type 2 certified. It has multiple levels of data security and redundant backup systems. Laker Software provides a full set of robust capabilities, including: Claims Processing/Adjudication, Call Center, Plan Set Up, Eligibility, Accumulator, Accounts Payable/Receivable, Prior Authorization, Reporting. Customers will begin to beta test some of the platform's newest features shortly, and other enhancements will follow as the next generation of Laker Software evolves. Customers can expect to see improvements in cost reduction due to automation, solutions for improved plan design and channel management, and advanced analytics and statistical analyses. This is in addition to a cloud-based infrastructure and redesigned user interface, allowing for even more flexibility and a better customer experience.Major Estimate Revision • Apr 27Consensus EPS estimates fall by 67%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$20.9b to US$22.1b. Forecast EPS reduced from -US$3.61 to -US$6.03 per share. Consumer Retailing industry in the US expected to see average net income growth of 10% next year. Consensus price target of US$2.50 unchanged from last update. Share price fell 8.9% to US$2.16 over the past week.Reported Earnings • Apr 20Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: US$13.72 loss per share (further deteriorated from US$9.96 loss in FY 2022). Revenue: US$24.1b (down 1.9% from FY 2022). Net loss: US$749.9m (loss widened 39% from FY 2022). Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 31%. Revenue is expected to decline by 2.0% p.a. on average during the next 2 years, while revenues in the Consumer Retailing industry in the US are expected to grow by 4.4%. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.Price Target Changed • Apr 02Price target decreased by 22% to US$3.00Down from US$3.83, the current price target is an average from 2 analysts. New target price is 34% above last closing price of US$2.24. Stock is down 73% over the past year. The company is forecast to post a net loss per share of US$10.49 next year compared to a net loss per share of US$9.96 last year.お知らせ • Jan 14Department of Justice Intervenes in Baron & Budd Whistleblower Lawsuit Against Rite AidLaw firm of Baron & Budd announced the U.S. Department of Justice has decided to intervene and take primary responsibility litigating a whistleblower lawsuit filed against Rite Aid for violations of the False Claims Act and the Controlled Substances Act. The whistleblowers in this case are former Rite Aid pharmacy employees represented by Baron & Budd. The lawsuit alleges the company knowingly dispensed controlled substances outside the usual course of the professional practice of pharmacy and without a legitimate medical purpose and billed government healthcare programs for the fraudulently dispensed prescriptions. The whistleblowers allege that “Rite Aid formally and informally incentivized and pressured its pharmacists to fill all prescriptions presented at its pharmacies – regardless of validity – resulting in prescriptions that were clearly not medically necessary being filled and billed to Government Programs, the public health and public fisc be damned.” The lawsuit alleges that taxpayer-funded health care programs, such as Medicare, Medicaid, and Tricare, only cover the costs of valid prescriptions issued for legitimate medical purposes, but these programs have paid out billions of dollars for medically unnecessary opioid prescriptions filled by Rite Aid pharmacies. The suit also alleges that, as an operator of a large network of retail pharmacies, Rite Aid had the capability, data, and information to help inform safe and responsible opioid dispensing practices, but the company chose the bottom line over the safety of the communities in which it operates. The suit alleges that Rite Aid consistently disregarded its duties to provide adequate staffing, resources, and information to its pharmacists and did not properly identify, investigate, and resolve red flag prescriptions before dispensing. Instead, the suit alleges that Rite Aid routinely chose profits over people, and created an environment where pharmacists were expected to dispense any and all prescriptions to fuel Rite Aid’s business interests.お知らせ • Jan 10+ 2 more updatesRite Aid Corporation Announces Departure of Heyward Donigan as President and as A Member of the BoardRite Aid Corporation announced Heyward Donigan’s departure from the Company as President and as a member of the Board.Seeking Alpha • Jan 09Rite Aid names interim CEO as Heyward Donigan departsHealthcare industry expert Elizabeth Burr has been elected as interim CEO at U.S. drugstore chain Rite Aid (NYSE:RAD), effective immediately. Burr, a member of the company’s board, will succeed president and CEO Heyward Donigan, who has left the company. She has extensive experience in the health industry, having previously served as VP, Head of Health Ventures and Chief Innovation Officer at Humana. The firm has initiated a search to identify a permanent CEO and has retained a leading executive search firm. In addition, Rite Aid (RAD) reiterated its fiscal 2023 financial guidance for total revenues of $23.7B and $24B vs. $21.63B consensus, net loss between $584M and $551M, adjusted EBITDA between $410M and $440M and capital expenditures of ~$225M. RAD shares gained 2% in Monday's premarket sessionPrice Target Changed • Jan 04Price target decreased to US$3.67Down from US$4.00, the current price target is an average from 3 analysts. New target price is 9.8% above last closing price of US$3.34. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$10.28 next year compared to a net loss per share of US$9.96 last year.Price Target Changed • Dec 22Price target decreased to US$3.83Down from US$4.17, the current price target is an average from 3 analysts. New target price is 12% above last closing price of US$3.43. Stock is down 75% over the past year. The company is forecast to post a net loss per share of US$10.28 next year compared to a net loss per share of US$9.96 last year.お知らせ • Dec 22Rite Aid Corporation Provides Earnings Guidance for the Fiscal Year 2023Rite Aid Corporation provided earnings guidance for the fiscal year 2023. For the year, total revenues are expected to be between $23.7 billion and $24.0 billion in fiscal 2023. Retail Pharmacy Segment revenue is expected to be between $17.4 billion and $17.6 billion and Pharmacy Services Segment revenue is expected to be between $6.3 billion and $6.4 billion (net of any intercompany revenues to the Retail Pharmacy Segment). Net loss is expected to be between $584 million and $551 million.Seeking Alpha • Dec 20Rite Aid Q3 2023 Earnings PreviewRite Aid (NYSE:RAD) is scheduled to announce Q3 earnings results on Wednesday, December 21st, before market open. The consensus EPS Estimate is -$0.31 and the consensus Revenue Estimate is $5.94B (-4.7% Y/Y). Over the last 2 years, RAD has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 1 upward revision and 1 downward.お知らせ • Dec 08Rite Aid Corporation to Report Q3, 2023 Results on Dec 21, 2022Rite Aid Corporation announced that they will report Q3, 2023 results at 9:30 AM, US Eastern Standard Time on Dec 21, 2022お知らせ • Nov 22Bronstein, Gewirtz & Grossman, LLC Notifies Rite Aid Corporation (RAD) Investors of Class Action and Encourages Investors to Actively ParticipateAttorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Rite Aid Corporation and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Rite Aid securities between April 14, 2022 and September 28, 2022, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the Securities Exchange Act of 1934. The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: despite representations to the contrary, the number of new members that the Elixir PBM services business was adding during the selling season ending on January 1, 2023 was in material decline; Rite Aid was likely to recognize a significant charge for the impairment of goodwill related to Elixir due to a decrease in "lives" covered by Elixir's PBM services business; and as a result, the Company's public statements were materially false and misleading at all relevant times.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Bari Harlam was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Nov 15Rite Aid spikes 20% on above average volumeThe beaten-down pharmacy retailer Rite Aid Corporation (NYSE:RAD) climbed ~20% Tuesday on above-average volume, rallying alongside a buoyant broader market. About 3.0M Rite Aid (RAD) shares have changed hands compared to the 65-day average volume of ~2.6M. However, with its stock continuing to trade ~48% below the year-ago level, Rite Aid (RAD) shares have yet to surpass the mid-September levels. About 18% of the company’s float represents short interest. The rally coincides with gains in the major indices after Walmart (WMT) topped Street forecasts with its Q3 2022 results, and data on producer prices indicated signs of moderating inflation. Wall Street has remained bearish on Rite Aid (RAD) stock, with an average rating of Strong Sell from analysts. However, the Seeking Alpha Author ratings identify RAD as a Hold alongside SA’s Quant System, which consistently beats the market.お知らせ • Oct 25Bronstein, Gewirtz & Grossman, LLC Files Lawsuit Against Rite Aid Corporation and Certain of Its OfficersBronstein, Gewirtz & Grossman, LLC notified investors that a class action lawsuit has been filed against Rite Aid Corporation and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Rite Aid securities between March 16, 2018 and August 29, 2022, both dates inclusive (the Class Period). This class action seeks to recover damages against Defendants for alleged violations of the Securities Exchange Act of 1934 (the Exchange Act). The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) despite representations to the contrary, the number of new members (lives) that the Elixir PBM services business was adding during the selling season ending on January 1, 2023 was in material decline; (2) Rite Aid was likely to recognize a significant charge for the impairment of goodwill related to Elixir due to a decrease in "lives" covered by Elixir's PBM services business; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.お知らせ • Oct 21Rite Aid Corporation Investors with Substantial Losses Have Opportunity to Lead the Rite Aid Class Action LawsuitRobbins Geller Rudman & Dowd LLP announced that purchasers or acquirers of Rite Aid Corporation securities between April 14, 2022 and September 28, 2022, inclusive (the Class Period) have until December 19, 2022 to seek appointment as lead plaintiff in the Rite Aid class action lawsuit. Captioned Page v. Rite Aid Corporation, No. 22-cv-04201 (E.D. Pa.), the Rite Aidclass action lawsuit charges Rite Aid and certain of its top executives with violations of the Securities Exchange Act of 1934. Case Allegations: Rite Aid operates through two segments, Retail Pharmacy and Pharmacy Services. Rite Aid’s Pharmacy Services segment provides an integrated suite of pharmacy benefit management (“PBM”) offerings through, among other things, Rite Aid’s Elixir subsidiary, including technology solutions, mail delivery services, specialty pharmacy, network and rebate administration, claims adjudication, and pharmacy discount programs. The Rite Aid class action lawsuit alleges that defendants throughout the Class Period failed to disclose that: (i) despite representations to the contrary, the number of new members (lives) that the Elixir PBM services business was adding during the selling season ending on January 1, 2023 was in material decline; and (ii) Rite Aid was likely to recognize a significant charge for the impairment of goodwill related to Elixir due to a decrease in “lives” covered by Elixir’s PBM services business. On September 29, 2022, Rite Aid announced a $252.2 million charge for the impairment of goodwill related to Rite Aid’s Elixir subsidiary. On an earnings call held later in the day, Rite Aid’s CFO, defendant Matt Schroeder, explained that the large impairment charge was related to Elixir based on “an update to estimate of lives for 2023 based on the latest selling season,” and that Rite Aid “expect[ed] lives to go down.” On this news, Rite Aid’s stock price fell by more than 28.02%, damaging investors. The Lead Plaintiff Process: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rite Aid securities during the Class Period to seek appointment as lead plaintiff in the Ride Aid class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rite Aid class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rite Aid class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rite Aid class action lawsuit.Seeking Alpha • Oct 11Rite Aid partners with Google Cloud on pharmacy insights, customer engagementRite Aid (NYSE:RAD) has brokered a partnership with Google Cloud (NASDAQ:GOOG) that will provide the drug store chain with improved insights and customer experiences, as well as access to the Anthos platform for application deployment. Anthos will provide Rite Aid's (RAD) pharmacies with cloud computing capabilities on-site. In addition, it will support a vaccine scheduling tool, customer messaging infrastructure, and digital engagement platform. Rite Aid (RAD) will also benefit from Google Cloud's (GOOG) Retail Search product that provides customers with precise search results when shopping on the company's website. Also, Rite Aid (RAD) will migrate its enterprise data to Google Cloud (GOOG) using BigQuery which will provide improved insights into its finances, supply chain inventory, and customer information, powering data-driven decisions for its business operations. Check out why Seeking Alpha contributor WYCO Researcher rates Rite Aid (RAD) a hold.Reported Earnings • Sep 30Second quarter 2023 earnings: EPS misses analyst expectationsSecond quarter 2023 results: US$6.07 loss per share (further deteriorated from US$1.86 loss in 2Q 2022). Revenue: US$5.90b (down 3.5% from 2Q 2022). Net loss: US$331.3m (loss widened 230% from 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to stay flat during the next 3 years compared to a 4.3% growth forecast for the Consumer Retailing industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.お知らせ • Sep 30Rite Aid Corporation Announces Impairment Charges for the Second Quarter Ended August 27, 2022Rite Aid Corporation announced impairment charges for the second quarter ended August 27, 2022. For the quarter, the company reported goodwill and intangible asset impairment charges of $252,200,000.財務状況分析短期負債: RADC.Qは マイナスの株主資本 を有しており、これは 短期資産 が 短期負債 をカバーしていないことよりも深刻な状況です。長期負債: RADC.Qは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。デット・ツー・エクイティの歴史と分析負債レベル: RADC.Qは 株主資本がマイナス となっており、これは高い負債レベルよりも深刻な状況です。負債の削減: RADC.Qの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: 現在のフリーキャッシュフローに基づいて、 RADC.Qに十分なキャッシュランウェイがあるかどうかを判断するにはデータが不十分です。キャッシュランウェイの予測: RADC.Qの フリー キャッシュ フロー が過去のレートに基づいて増加または減少し続ける場合、十分な キャッシュ ランウェイ があるかどうかを判断するためのデータが不十分です。健全な企業の発掘7D1Y7D1Y7D1YConsumer-retailing 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/09/03 11:28終値2024/09/03 00:00収益2023/09/02年間収益2023/03/04データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Rite Aid Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Steven ValiquetteBofA Global ResearchWilliam FrohnhoeferBTIGGeorge HillDeutsche Bank13 その他のアナリストを表示
お知らせ • Mar 30+ 4 more updatesMotion for Asset Sale Approved for Rite Aid CorporationThe US Bankruptcy Court gave an order approving the sale of the certain real property of Rite Aid Corporation on March 28, 2024. The debtor has been authorized to sell its certain assets to Moshe Faour, for a purchase price of $3.03 million. The debtor’s assets include Sale of Certain Real Property Located at 101 Main Street, Sayville, New York.
お知らせ • Jan 13Rite Aid Corporation announced delayed 10-Q filingOn 01/12/2024, Rite Aid Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 18+ 4 more updatesNYSE Suspends Trading in Rite AidThe New York Stock Exchange LLC (“NYSE” or “Exchange”) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Rite Aid Corporation (the “Company”) — ticker symbol RAD — from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision that the Company’s common stock is no longer suitable for listing pursuant to Listed Company Manual Section 802.01D after the Company’s October 16, 2023 disclosure that the Company has filed voluntary petitions to commence proceedings under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of New Jersey. In reaching its delisting determination, NYSE Regulation noted that the restructuring term sheet contemplates that the Company’s equity holders are expected to receive no recovery. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the Company’s common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
お知らせ • Oct 17Rite Aid Corporation Filed for BankruptcyRite Aid Corporation, along with its 121 affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of New Jersey on October 15, 2023. The debtor listed both its assets and liabilities in the range of $1 billion to $10 billion. The debtor is represented by Michael D. Sirota of Cole Schotz P.C., Kirkland & Ellis LLP and Kirkland & Ellis International LLP as its legal counsels. The debtor also hired Guggenheim Partners as its investment banker, Alvarez & Marsal North America, LLC as its financial, tax, and restructuring advisor and Kroll Restructuring Administration as its notice and claims agent.
お知らせ • Oct 13Rite Aid Corporation announced delayed 10-Q filingOn 10/12/2023, Rite Aid Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 05+ 1 more updateRite Aid Corporation Receives Written Notice from the New York Stock ExchangeOn September 28, 2023, Rite Aid Corporation received written notice from the New York Stock Exchange that the Company is no longer in compliance with NYSE continued listing standards set in Section 802.01B and Section 802.01C of the NYSE’s Listed Company Manual due to the fact that (i) the Company’s average total market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million; and (ii) the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period. As described in the Notice, as of September 27, 2023, (a) the Company’s 30 trading-day average market capitalization was approximately $49.97 million and its last reported stockholders’ deficit as of June 3, 2023, was approximately $(947.4) million; and (b) the 30 trading-day average closing price of the Company’s common stock was $0.88 per share. Pursuant to the NYSE rules, the Company has ten business days from receipt of the Notice to send a letter to the NYSE confirming receipt of the Notice and to indicate whether it intends to cure the deficiencies. If the Company determines to cure such deficiencies, the Company would then submit a business plan within 45 days of receipt of the Notice that demonstrates compliance with the Minimum Market Capitalization Standard within 18 months of receipt of the Notice. Upon receipt of such plan, the NYSE would have up to 45 days to review and determine whether the Company has made a reasonable demonstration of its ability to come into conformity with the relevant standards within the cure period. The NYSE may either accept the plan, at which time the Company would be subject to ongoing quarterly monitoring for compliance with the plan, or the NYSE may not accept the plan and the Company would be subject to suspension and delisting proceedings. The Company has six months from receipt of the Notice, or until the Company’s next annual meeting of stockholders if stockholder approval is required, to regain compliance with the Minimum Stock Price Standard by bringing its share price and 30 trading-day average share price above $1.00. Pursuant to the NYSE’s Minimum Stock Price Standard rules, the Company can regain compliance with the Minimum Stock Price Standard if, on the last trading day of any calendar month during the six-month cure period after its receipt of the Notice, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. In the event that, at the expiration of the six-month cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. Under the NYSE rules, the Company’s common stock will continue to be listed and traded on the NYSE during the independent cure periods outlined above, subject to the Company’s compliance with other continued listing requirements. The current noncompliance with the NYSE listing standards does not affect the Company’s ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements, nor does it trigger any violation of its material debt or other obligations. As previously disclosed by the Company, including in its Quarterly Report on Form 10-Q for the quarter ended June 3, 2023, filed with the U.S. Securities and Exchange Commission on July 11, 2023, the Company has been engaged in reviewing and continues to review strategic alternatives to recapitalize, refinance or otherwise optimize its capital structure, which may ultimately result in the Company pursuing one or more significant corporate transactions or other remedial measures. The Ongoing Review includes an evaluation of available options to regain compliance with the NYSE’s continued listing standards. The Company can provide no assurances that it will be able to satisfy any of the steps outlined above and maintain the listing of its shares on the NYSE or the results of the Ongoing Review.
お知らせ • Sep 04Rite Aid Corporation Announces Resignation of Jeffrey S. Stein, as Chief Restructuring OfficerRite Aid Corporation announced Jeffrey S. Stein, who has stepped down as Chief Restructuring Officer in connection with the Company’s emergence from Chapter 11.
お知らせ • Apr 05Rite Aid Announces Availability of Opill At All LocationsRite Aid Corporation announced Opill, the first daily oral contraceptive FDA-approved for purchase without a prescription, is now available in all stores. Opill is a progestin-only, daily oral contraceptive (birth control pill) that’s safe and effective when used as directed to help prevent pregnancy. Opill over-the-counter birth control pills are available at Rite Aid for the suggested retail price of $19.99 for a one-month supply and $49.99 for a three-month supply. Both options are available for purchase at Rite Aid stores nationwide and online at RiteAid.com. There are no restrictions for purchasing Opill. Rite Aid pharmacists are available to answer any customer questions about Opill.
お知らせ • Mar 30+ 4 more updatesMotion for Asset Sale Approved for Rite Aid CorporationThe US Bankruptcy Court gave an order approving the sale of the certain real property of Rite Aid Corporation on March 28, 2024. The debtor has been authorized to sell its certain assets to Moshe Faour, for a purchase price of $3.03 million. The debtor’s assets include Sale of Certain Real Property Located at 101 Main Street, Sayville, New York.
お知らせ • Jan 31Rite Aid Corporation (OTCPK:RADC.Q) acquired Tuttles Pharmacy Inc from Pellegrini family.Rite Aid Corporation (OTCPK:RADC.Q) acquired Tuttles Pharmacy Inc. from Pellegrini family on January 29, 2024.Rite Aid Corporation (OTCPK:RADC.Q) completed the acquisition of Tuttles Pharmacy Inc. from Pellegrini family on January 29, 2024.
お知らせ • Jan 13Rite Aid Corporation announced delayed 10-Q filingOn 01/12/2024, Rite Aid Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 21Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Rite Aid Corporation Securities LitigationThe following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Rite Aid Securities Litigation: Investor purchased or acquired Rite Aid Corporation (Rite Aid) common stock between October 20, 2016 and June 28, 2017, inclusive (the “class”), investor could receive a payment from a class action settlement. Certain persons are excluded from the definition of the class as set forth in the stipulation of settlement. Pursuant to Rule 23 of the Federal Rules of Civil Procedure and by Order of the United States District Court for the Middle District of Pennsylvania, that in the above-captioned litigation (the “Action”), which is a certified class action, a Settlement has been proposed for $192,500,000.00 in cash. A hearing will be held on February 7, 2024, at 1:30 p.m., before the Honorable Jennifer P. Wilson, in Courtroom 8A, at the United States District Court for the Middle District of Pennsylvania, Sylvia H. Rambo U.S. Courthouse, 1501 North 6th Street, Harrisburg, PA 17102, for the purpose of determining whether: (1) the proposed Settlement should be approved by the Court as fair, reasonable, and adequate; (2) the proposed Plan of Allocation for distribution of the Settlement proceeds is fair, reasonable, and adequate and therefore should be approved; and (3) the application of Lead Counsel for the payment of attorneys’ fees and expenses from the Settlement Fund, including interest earned thereon, and requests by Plaintiffs for their time and expenses, should be approved.
お知らせ • Oct 21Rite Aid Corporation Announces Board AppointmentsOn October 15, 2023, Rite Aid Corporation appointed Carrie Teffner and Paul Keglevic to the Company’s Board of Directors. Upon appointment, Mr. Keglevic and Ms. Teffner joined the Audit Committee of the Board, where Mr. Keglevic will serve as Chair. Ms. Teffner was also appointed as a member of the Compensation Committee of the Board. In connection with their respective appointments, Ms. Teffner and Mr. Keglevic will each be entitled to receive a cash directors’ fee equal to $50,000 per month, payable in arrears, and reimbursement for travel and lodging expenses associated with the directors’ services on the Board. Ms. Teffner has over 30 years of strategic, financial and operational leadership experience assisting retail and consumer product companies in driving growth and profitability. She has deep expertise leading successful large-scale transformation initiatives and has served as Executive Vice President and Chief Financial Officer at several Fortune 500 companies. Ms. Teffner currently serves on the boards of DXC Technology, International Data Group and BFA Industries. She previously served on the boards of Ascena Retail Group, Avaya and GameStop. Mr. Keglevic is an NACD-certified director with over 45 years of leadership experience and deep expertise in finance and accounting, operational improvement and turnarounds, restructuring and risk management across a range of industries. He has served as CEO, CFO, Chief Restructuring Officer and Chief Risk Officer at numerous companies, most recently as CEO of Energy Future Holdings. Earlier in his career, Mr. Keglevic was a Partner and member of the U.S. leadership team at PricewaterhouseCoopers. He currently serves on the boards of WeWork, Evergy and Envision Healthcare. Mr. Keglevic previously served on the boards of Ascena Retail Group, Bonanza Creek Energy, Clear Channel Holdings, Cobalt International Energy and Frontier Communications, among others. Prior to their respective appointments, Ms. Teffner and Mr. Keglevic, each entered into a letter agreement with the Company, dated as of July 5, 2023, pursuant to which Ms. Teffner and Mr. Keglevic provided consulting services to the Company on matters relating to refinancing, restructuring and deleveraging for the period between July 5, 2023 until their respective appointments on October 15, 2023. During such time, Ms. Teffner and Mr. Keglevic each received $200,000 in the aggregate, consisting of monthly fees payable by the Company pursuant to their respective letter agreements.
お知らせ • Oct 20Rite Aid Corporation(OTCPK:RADC.Q) dropped from S&P TMI IndexRite Aid Corporation(OTCPK:RADC.Q) dropped from S&P TMI Index
お知らせ • Oct 19+ 1 more updateRite Aid Corporation(OTCPK:RADC.Q) dropped from S&P Global BMI IndexRite Aid Corporation(OTCPK:RADC.Q) dropped from S&P Global BMI Index
お知らせ • Oct 18+ 4 more updatesNYSE Suspends Trading in Rite AidThe New York Stock Exchange LLC (“NYSE” or “Exchange”) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Rite Aid Corporation (the “Company”) — ticker symbol RAD — from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision that the Company’s common stock is no longer suitable for listing pursuant to Listed Company Manual Section 802.01D after the Company’s October 16, 2023 disclosure that the Company has filed voluntary petitions to commence proceedings under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of New Jersey. In reaching its delisting determination, NYSE Regulation noted that the restructuring term sheet contemplates that the Company’s equity holders are expected to receive no recovery. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the Company’s common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
お知らせ • Oct 17Rite Aid Corporation Filed for BankruptcyRite Aid Corporation, along with its 121 affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of New Jersey on October 15, 2023. The debtor listed both its assets and liabilities in the range of $1 billion to $10 billion. The debtor is represented by Michael D. Sirota of Cole Schotz P.C., Kirkland & Ellis LLP and Kirkland & Ellis International LLP as its legal counsels. The debtor also hired Guggenheim Partners as its investment banker, Alvarez & Marsal North America, LLC as its financial, tax, and restructuring advisor and Kroll Restructuring Administration as its notice and claims agent.
Seeking Alpha • Oct 16Rite Aid Shareholders Are Wiped Out Under A Chapter 11 Bankruptcy PlanSummary Rite Aid File for Ch.11 bankruptcy on October 15. Under the plan shareholders get no recovery and shares will be cancelled. There is a stalking horse bid of $575 million for Elixir. Secured noteholders get 100% of the new equity. McKesson is trying to terminate their supply contract with Rite Aid. Read the full article on Seeking Alpha
お知らせ • Oct 13Rite Aid Corporation announced delayed 10-Q filingOn 10/12/2023, Rite Aid Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 05+ 1 more updateRite Aid Corporation Receives Written Notice from the New York Stock ExchangeOn September 28, 2023, Rite Aid Corporation received written notice from the New York Stock Exchange that the Company is no longer in compliance with NYSE continued listing standards set in Section 802.01B and Section 802.01C of the NYSE’s Listed Company Manual due to the fact that (i) the Company’s average total market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million; and (ii) the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period. As described in the Notice, as of September 27, 2023, (a) the Company’s 30 trading-day average market capitalization was approximately $49.97 million and its last reported stockholders’ deficit as of June 3, 2023, was approximately $(947.4) million; and (b) the 30 trading-day average closing price of the Company’s common stock was $0.88 per share. Pursuant to the NYSE rules, the Company has ten business days from receipt of the Notice to send a letter to the NYSE confirming receipt of the Notice and to indicate whether it intends to cure the deficiencies. If the Company determines to cure such deficiencies, the Company would then submit a business plan within 45 days of receipt of the Notice that demonstrates compliance with the Minimum Market Capitalization Standard within 18 months of receipt of the Notice. Upon receipt of such plan, the NYSE would have up to 45 days to review and determine whether the Company has made a reasonable demonstration of its ability to come into conformity with the relevant standards within the cure period. The NYSE may either accept the plan, at which time the Company would be subject to ongoing quarterly monitoring for compliance with the plan, or the NYSE may not accept the plan and the Company would be subject to suspension and delisting proceedings. The Company has six months from receipt of the Notice, or until the Company’s next annual meeting of stockholders if stockholder approval is required, to regain compliance with the Minimum Stock Price Standard by bringing its share price and 30 trading-day average share price above $1.00. Pursuant to the NYSE’s Minimum Stock Price Standard rules, the Company can regain compliance with the Minimum Stock Price Standard if, on the last trading day of any calendar month during the six-month cure period after its receipt of the Notice, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. In the event that, at the expiration of the six-month cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. Under the NYSE rules, the Company’s common stock will continue to be listed and traded on the NYSE during the independent cure periods outlined above, subject to the Company’s compliance with other continued listing requirements. The current noncompliance with the NYSE listing standards does not affect the Company’s ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements, nor does it trigger any violation of its material debt or other obligations. As previously disclosed by the Company, including in its Quarterly Report on Form 10-Q for the quarter ended June 3, 2023, filed with the U.S. Securities and Exchange Commission on July 11, 2023, the Company has been engaged in reviewing and continues to review strategic alternatives to recapitalize, refinance or otherwise optimize its capital structure, which may ultimately result in the Company pursuing one or more significant corporate transactions or other remedial measures. The Ongoing Review includes an evaluation of available options to regain compliance with the NYSE’s continued listing standards. The Company can provide no assurances that it will be able to satisfy any of the steps outlined above and maintain the listing of its shares on the NYSE or the results of the Ongoing Review.
お知らせ • Sep 26Rite Aid Corporation is Heading Towards BankruptcyRite Aid Corporation is heading towards bankruptcy, as of September 22, 2023. Company is expected to file a Chapter 11 bankruptcy petition within the next couple of days as it nears an agreement with existing creditors. The company is finalizing a reorganization pact with its largest creditors/ is leading towards a bankruptcy proceeding under Chapter 11.
お知らせ • Sep 16Rite Aid and Bartell Drugs Announce Availability of Appointments for Updated COVID-19 VaccineRite Aid announced that scheduling is now available for eligible customers seeking the updated COVID-19 (2023-2024) vaccines at its locations and at Bartell Drugs locations in the Pacific Northwest. Appointments are available beginning on September 22. The updated COVID-19 vaccine provides enhanced protection against currently circulating variants of COVID-19. The vaccine is recommended for individuals six months and older. An updated COVID-19 vaccine is needed for those who have not received a COVID-19 vaccine in the past two months, according to the CDC. Rite Aid pharmacists are trained to immunize customers ages three and older. Other immunizations, including the flu vaccine, can also be scheduled via the online scheduling tool. Both the COVID-19 and flu vaccinations can be administered during the same appointment.
お知らせ • Sep 12Rite Aid Announces Availability of OTC NARCAN Nasal Spray At All LocationsRite Aid announced that NARCAN Nasal Spray, a medication used to reverse the effects of an opioid overdose, is available at all locations nationwide, including Bartell Drugs in the Pacific Northwest. NARCAN Nasal Spray can be purchased over the counter without a prescription. NARCAN Nasal spray (naloxone HCl 4 mg) is a medication designed to rapidly reverse the effects of a life-threatening opioid emergency and is the standard treatment for opioid overdose. It is now FDA-approved for OTC use and is available for purchase at Rite Aid stores nationwide and online at Rite Aid.com. Each carton of NARCAN Nasal Spray contains two single-dose devices. Each device contains one dose of medicine. The carton is readily available on shelves and at the pharmacy counter at Rite Aid stores and is priced at $45.99.
お知らせ • Aug 05Rite Aid Corporation Announces Availability of Flu and RSV Vaccine Appointments at All LocationsRite Aid Corporation announced appointments for flu and RSV vaccines are available at all store locations, including Bartell Drugs in the Pacific Northwest. Customers can now schedule appointments to protect themselves and family members against the upcoming respiratory virus season through Rite Aid's online scheduler. Rite Aid will be offering flu vaccines protecting against the strains of influenza that are expected to circulate in the United States this year, as well as Flumist, a nasal spray flu vaccine, which is in limited supply at all locations. Customers receiving their flu shot will get a coupon for $5 off a $25 in-store purchase from now until Sept. 30, 2023. This offer excludes stores in New York or New Jersey and some restrictions apply. The Centers for Disease Control (CDC) recommends adults 60 years and older receive a single dose of RSV vaccine, based on discussions with their pharmacist or other healthcare provider. The RSV vaccine may be given at the same time as other vaccines. Rite Aid and Bartell Drugs also offer COVID-19 and other routine vaccinations at all locations, helping customers and families stay up to date on vaccines that provide critical protection against certain diseases, some of which are required for certain ages, activities or for overseas travel. Rite Aid and Bartell drugs will provide the new CDC-recommended COVID-19 vaccine once available, which will better protect against the most prevalent COVID-19 strain. Rite Aid pharmacists can provide additional guidance on which vaccines are right for each customer and advise on the timing of administration of each vaccine. To help customers assess their needs for routine immunizations, Rite Aid offers an Immunization Evaluation Questionnaire on its website. The questionnaire guides customers to ensure they are up to date with all necessary immunizations based on their age, conditions, or occupation. Rite Aid and Bartell's pharmacists can immunize adults and children three years of age and older against influenza. To schedule an appointment for a flu vaccine or other immunizations, Rite Aid customers can use the online scheduling tool at Rite Aid.com. Bartell Drugs customers can use the online scheduling tools linked here. All locations are currently accepting walk-ins. How online scheduling works: Using the online scheduling tool, customers may select a convenient time and location to schedule a vaccine appointment for flu, COVID-19 and other recommended vaccinations. Customers supply necessary information and consent forms securely online in advance of their appointment. Reminders will be sent in the days leading up to the appointment via customers' chosen communication preferences by text or email.
New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$947m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$383m). Currently unprofitable and not forecast to become profitable over next 3 years (US$233m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change).
お知らせ • Aug 02Rite Aid Corporation Announces Executive ChangesRite Aid Corporation announced that on July 28, 2023, Justin Mennen, the EVP and Chief Digital and Technology Officer of the Company, ceased to be employed by the Company, effective immediately.
お知らせ • Jul 13Rite Aid Corporation, Annual General Meeting, Jul 26, 2023Rite Aid Corporation, Annual General Meeting, Jul 26, 2023.
Seeking Alpha • Jul 10Rite Aid May Be Forced Into Ch.11 Bankruptcy To Resolve Opioid LiabilitiesSummary Rite Aid's stock is being downgraded from "Hold" to "Sell" due to the opioid lawsuit, ongoing financial losses, and ineffective management. Rite Aid reported a $(5.56) net loss per share for 1Q. Elixir will discontinue their Medicare Part D program for individuals starting next year. The stock is effectively trading at only about $0.08 after adjusting for the 1-20 reverse stock split a few years ago. Read the full article on Seeking Alpha
Major Estimate Revision • Jul 06Consensus EPS estimates fall by 52%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$21.8b to US$22.7b. Forecast EPS reduced from -US$8.23 to -US$12.50 per share. Consumer Retailing industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$1.50 to US$1.00. Share price fell 4.6% to US$1.46 over the past week.
New Risk • Jul 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$947m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$383m). Currently unprofitable and not forecast to become profitable over next 2 years (US$292m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (US$83.4m market cap).
お知らせ • Jun 30+ 2 more updatesRite Aid Corporation, Annual General Meeting, Aug 18, 2023Rite Aid Corporation, Annual General Meeting, Aug 18, 2023, at 11:30 US Eastern Standard Time. Agenda: To consider the Election of six directors to hold office until the 2024 Annual Meeting of Stockholders the Board's nominees; to consider Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm; to consider Advisory vote to approve the compensation of our named executive officers; to consider Advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers; to consider Approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions; to Consider and vote on a stockholder proposal to require an annual advisory vote on the compensation of Rite Aid's directors, if properly presented at the Annual Meeting; and to consider other business matters.
Reported Earnings • Jun 29First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2024 results: US$5.56 loss per share (further deteriorated from US$2.03 loss in 1Q 2023). Revenue: US$5.65b (down 6.0% from 1Q 2023). Net loss: US$306.7m (loss widened 178% from 1Q 2023). Revenue exceeded analyst estimates by 8.1%. Earnings per share (EPS) missed analyst estimates by 130%. Revenue is expected to decline by 1.4% p.a. on average during the next 3 years, while revenues in the Consumer Retailing industry in the US are expected to grow by 4.2%. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
Seeking Alpha • Jun 27Rite Aid Q1 Earnings Preview: Bears Remain In ControlSummary Bears remain resolute in their strong bet against Rite Aid. Weak outlook from Walgreens hurt RAD stock ahead of the Q1 2024 report. Debt leverage and cost run rate remain a concern. Read the full article on Seeking Alpha
お知らせ • Jun 25+ 1 more updateRite Aid Corporation(NYSE:RAD) dropped from Russell Small Cap Comp Growth IndexRite Aid Corporation(NYSE:RAD) dropped from Russell Small Cap Comp Growth Index
お知らせ • Jun 13Rite Aid Corporation to Report Q1, 2024 Results on Jun 29, 2023Rite Aid Corporation announced that they will report Q1, 2024 results on Jun 29, 2023
お知らせ • Jun 10Rite Aid Corporation Names Thomas Sabatino Chief Legal OfficerRite Aid announced that Thomas Sabatino has joined the company as Executive Vice President and Chief Legal Officer. Sabatino will play a pivotal role in the company’s growth strategy to help create meaningful customer, client, and member experiences for millions of Americans. As Chief Legal Officer, he will oversee the organization’s legal affairs, including enterprise risk management, compliance, regulatory affairs, and privacy. Sabatino will become a member of the company's executive leadership team and report to Burr. He brings four decades of experience in the legal field navigating complex business needs. He was most recently the Executive Vice President and General Counsel at Tenneco Inc. His expertise runs deep in the healthcare industry with previous executive roles at Aetna, Walgreen Boots Alliance, Schering Plough Corp., and Baxter International Inc., where in each instance he was instrumental in driving large-scale growth and operational effectiveness. Sabatino currently serves as a member of the Board of Directors of the Humane Society of the United States and the South Florida Wildlife Center. He is Chair Emeritus of the International Institute for Conflict Prevention and Resolution and is on the Board of Advisors of the University of Pennsylvania Carey School of Law.
お知らせ • Jun 06Rite Aid Announces Launch of RYSHI Beauty and Personal Care EssentialsRite Aid announced the launch of RYSHI™? - its exclusive collection of clean beauty and personal care essentials designed to let the real shine through. Spanning across multiple categories, RYSHI™? products offer better-for-you ingredients at an accessible price point so customers can conveniently build their beauty toolkit at their neighborhood Rite Aid. The full collection offers a vast range of products so customers can find answers to all their beauty and grooming needs under one trusted brand. From vegan lashes to hydrogel eye and sheet masks, to sunscreen, body wash, and razors, RYSHI™®? everyday essentials and self-pampering favorites are all priced under $20 to provide accessible, high-quality offerings to Rite Aid customers. To help customers embrace their true self and feel confident, radiant and clean, the RYSHI™? brand features a wide selection of products, including: Gua Shas/Facial Massagers, Facial Wipes, Hydrogel Eye Masks, Sheet Masks, Vegan Eye Lashes, Makeup Applicators, Eyelash Curlers, Hand Cream, Body Wash, Cotton Balls/Rounds, Sunscreen, Dry Brushes, Nail Care, Razors.Rite Aid created RYSHI™? with a commitment to clean and quality products. The collection is free from ingredients of concern such as parabens, perfluorinated substances (PFAS), triclosan, formaldehyde and formaldehyde releasers. In addition, all RYSHI™? product are independently lab tested to ensure product performance and safety and are backed by a 100% satisfaction guarantee. RYSHI™? will continue to expand its offerings through 2023, boasting more than 300 products--exclusively available at Rite Aid stores and on Rite Aid.com.
お知らせ • May 24Elixir Announces the Next Wave of Innovation for Pharmacy Benefits Technology PlatformElixir has announced details of the next release of its Laker Software technology platform. The upcoming enhancements include new automated workflows, a customer service tool and modernization of the user interface. The upgrade will include a range of advanced functionalities that are designed to help customers better manage their pharmacy claims adjudication data and streamline workflows. The new features will allow users to access and share data more efficiently, collaborate more effectively, and improve productivity. Built on a resilient, scalable architecture, the Laker Software platform is a 100% virtualized environment. The platform processes millions of paid claims per year and is SOC 1 Type 2 certified. It has multiple levels of data security and redundant backup systems. Laker Software provides a full set of robust capabilities, including: Claims Processing/Adjudication, Call Center, Plan Set Up, Eligibility, Accumulator, Accounts Payable/Receivable, Prior Authorization, Reporting. Customers will begin to beta test some of the platform's newest features shortly, and other enhancements will follow as the next generation of Laker Software evolves. Customers can expect to see improvements in cost reduction due to automation, solutions for improved plan design and channel management, and advanced analytics and statistical analyses. This is in addition to a cloud-based infrastructure and redesigned user interface, allowing for even more flexibility and a better customer experience.
Major Estimate Revision • Apr 27Consensus EPS estimates fall by 67%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$20.9b to US$22.1b. Forecast EPS reduced from -US$3.61 to -US$6.03 per share. Consumer Retailing industry in the US expected to see average net income growth of 10% next year. Consensus price target of US$2.50 unchanged from last update. Share price fell 8.9% to US$2.16 over the past week.
Reported Earnings • Apr 20Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: US$13.72 loss per share (further deteriorated from US$9.96 loss in FY 2022). Revenue: US$24.1b (down 1.9% from FY 2022). Net loss: US$749.9m (loss widened 39% from FY 2022). Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 31%. Revenue is expected to decline by 2.0% p.a. on average during the next 2 years, while revenues in the Consumer Retailing industry in the US are expected to grow by 4.4%. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.
Price Target Changed • Apr 02Price target decreased by 22% to US$3.00Down from US$3.83, the current price target is an average from 2 analysts. New target price is 34% above last closing price of US$2.24. Stock is down 73% over the past year. The company is forecast to post a net loss per share of US$10.49 next year compared to a net loss per share of US$9.96 last year.
お知らせ • Jan 14Department of Justice Intervenes in Baron & Budd Whistleblower Lawsuit Against Rite AidLaw firm of Baron & Budd announced the U.S. Department of Justice has decided to intervene and take primary responsibility litigating a whistleblower lawsuit filed against Rite Aid for violations of the False Claims Act and the Controlled Substances Act. The whistleblowers in this case are former Rite Aid pharmacy employees represented by Baron & Budd. The lawsuit alleges the company knowingly dispensed controlled substances outside the usual course of the professional practice of pharmacy and without a legitimate medical purpose and billed government healthcare programs for the fraudulently dispensed prescriptions. The whistleblowers allege that “Rite Aid formally and informally incentivized and pressured its pharmacists to fill all prescriptions presented at its pharmacies – regardless of validity – resulting in prescriptions that were clearly not medically necessary being filled and billed to Government Programs, the public health and public fisc be damned.” The lawsuit alleges that taxpayer-funded health care programs, such as Medicare, Medicaid, and Tricare, only cover the costs of valid prescriptions issued for legitimate medical purposes, but these programs have paid out billions of dollars for medically unnecessary opioid prescriptions filled by Rite Aid pharmacies. The suit also alleges that, as an operator of a large network of retail pharmacies, Rite Aid had the capability, data, and information to help inform safe and responsible opioid dispensing practices, but the company chose the bottom line over the safety of the communities in which it operates. The suit alleges that Rite Aid consistently disregarded its duties to provide adequate staffing, resources, and information to its pharmacists and did not properly identify, investigate, and resolve red flag prescriptions before dispensing. Instead, the suit alleges that Rite Aid routinely chose profits over people, and created an environment where pharmacists were expected to dispense any and all prescriptions to fuel Rite Aid’s business interests.
お知らせ • Jan 10+ 2 more updatesRite Aid Corporation Announces Departure of Heyward Donigan as President and as A Member of the BoardRite Aid Corporation announced Heyward Donigan’s departure from the Company as President and as a member of the Board.
Seeking Alpha • Jan 09Rite Aid names interim CEO as Heyward Donigan departsHealthcare industry expert Elizabeth Burr has been elected as interim CEO at U.S. drugstore chain Rite Aid (NYSE:RAD), effective immediately. Burr, a member of the company’s board, will succeed president and CEO Heyward Donigan, who has left the company. She has extensive experience in the health industry, having previously served as VP, Head of Health Ventures and Chief Innovation Officer at Humana. The firm has initiated a search to identify a permanent CEO and has retained a leading executive search firm. In addition, Rite Aid (RAD) reiterated its fiscal 2023 financial guidance for total revenues of $23.7B and $24B vs. $21.63B consensus, net loss between $584M and $551M, adjusted EBITDA between $410M and $440M and capital expenditures of ~$225M. RAD shares gained 2% in Monday's premarket session
Price Target Changed • Jan 04Price target decreased to US$3.67Down from US$4.00, the current price target is an average from 3 analysts. New target price is 9.8% above last closing price of US$3.34. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$10.28 next year compared to a net loss per share of US$9.96 last year.
Price Target Changed • Dec 22Price target decreased to US$3.83Down from US$4.17, the current price target is an average from 3 analysts. New target price is 12% above last closing price of US$3.43. Stock is down 75% over the past year. The company is forecast to post a net loss per share of US$10.28 next year compared to a net loss per share of US$9.96 last year.
お知らせ • Dec 22Rite Aid Corporation Provides Earnings Guidance for the Fiscal Year 2023Rite Aid Corporation provided earnings guidance for the fiscal year 2023. For the year, total revenues are expected to be between $23.7 billion and $24.0 billion in fiscal 2023. Retail Pharmacy Segment revenue is expected to be between $17.4 billion and $17.6 billion and Pharmacy Services Segment revenue is expected to be between $6.3 billion and $6.4 billion (net of any intercompany revenues to the Retail Pharmacy Segment). Net loss is expected to be between $584 million and $551 million.
Seeking Alpha • Dec 20Rite Aid Q3 2023 Earnings PreviewRite Aid (NYSE:RAD) is scheduled to announce Q3 earnings results on Wednesday, December 21st, before market open. The consensus EPS Estimate is -$0.31 and the consensus Revenue Estimate is $5.94B (-4.7% Y/Y). Over the last 2 years, RAD has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 1 upward revision and 1 downward.
お知らせ • Dec 08Rite Aid Corporation to Report Q3, 2023 Results on Dec 21, 2022Rite Aid Corporation announced that they will report Q3, 2023 results at 9:30 AM, US Eastern Standard Time on Dec 21, 2022
お知らせ • Nov 22Bronstein, Gewirtz & Grossman, LLC Notifies Rite Aid Corporation (RAD) Investors of Class Action and Encourages Investors to Actively ParticipateAttorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Rite Aid Corporation and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Rite Aid securities between April 14, 2022 and September 28, 2022, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the Securities Exchange Act of 1934. The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: despite representations to the contrary, the number of new members that the Elixir PBM services business was adding during the selling season ending on January 1, 2023 was in material decline; Rite Aid was likely to recognize a significant charge for the impairment of goodwill related to Elixir due to a decrease in "lives" covered by Elixir's PBM services business; and as a result, the Company's public statements were materially false and misleading at all relevant times.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Bari Harlam was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Nov 15Rite Aid spikes 20% on above average volumeThe beaten-down pharmacy retailer Rite Aid Corporation (NYSE:RAD) climbed ~20% Tuesday on above-average volume, rallying alongside a buoyant broader market. About 3.0M Rite Aid (RAD) shares have changed hands compared to the 65-day average volume of ~2.6M. However, with its stock continuing to trade ~48% below the year-ago level, Rite Aid (RAD) shares have yet to surpass the mid-September levels. About 18% of the company’s float represents short interest. The rally coincides with gains in the major indices after Walmart (WMT) topped Street forecasts with its Q3 2022 results, and data on producer prices indicated signs of moderating inflation. Wall Street has remained bearish on Rite Aid (RAD) stock, with an average rating of Strong Sell from analysts. However, the Seeking Alpha Author ratings identify RAD as a Hold alongside SA’s Quant System, which consistently beats the market.
お知らせ • Oct 25Bronstein, Gewirtz & Grossman, LLC Files Lawsuit Against Rite Aid Corporation and Certain of Its OfficersBronstein, Gewirtz & Grossman, LLC notified investors that a class action lawsuit has been filed against Rite Aid Corporation and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Rite Aid securities between March 16, 2018 and August 29, 2022, both dates inclusive (the Class Period). This class action seeks to recover damages against Defendants for alleged violations of the Securities Exchange Act of 1934 (the Exchange Act). The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) despite representations to the contrary, the number of new members (lives) that the Elixir PBM services business was adding during the selling season ending on January 1, 2023 was in material decline; (2) Rite Aid was likely to recognize a significant charge for the impairment of goodwill related to Elixir due to a decrease in "lives" covered by Elixir's PBM services business; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.
お知らせ • Oct 21Rite Aid Corporation Investors with Substantial Losses Have Opportunity to Lead the Rite Aid Class Action LawsuitRobbins Geller Rudman & Dowd LLP announced that purchasers or acquirers of Rite Aid Corporation securities between April 14, 2022 and September 28, 2022, inclusive (the Class Period) have until December 19, 2022 to seek appointment as lead plaintiff in the Rite Aid class action lawsuit. Captioned Page v. Rite Aid Corporation, No. 22-cv-04201 (E.D. Pa.), the Rite Aidclass action lawsuit charges Rite Aid and certain of its top executives with violations of the Securities Exchange Act of 1934. Case Allegations: Rite Aid operates through two segments, Retail Pharmacy and Pharmacy Services. Rite Aid’s Pharmacy Services segment provides an integrated suite of pharmacy benefit management (“PBM”) offerings through, among other things, Rite Aid’s Elixir subsidiary, including technology solutions, mail delivery services, specialty pharmacy, network and rebate administration, claims adjudication, and pharmacy discount programs. The Rite Aid class action lawsuit alleges that defendants throughout the Class Period failed to disclose that: (i) despite representations to the contrary, the number of new members (lives) that the Elixir PBM services business was adding during the selling season ending on January 1, 2023 was in material decline; and (ii) Rite Aid was likely to recognize a significant charge for the impairment of goodwill related to Elixir due to a decrease in “lives” covered by Elixir’s PBM services business. On September 29, 2022, Rite Aid announced a $252.2 million charge for the impairment of goodwill related to Rite Aid’s Elixir subsidiary. On an earnings call held later in the day, Rite Aid’s CFO, defendant Matt Schroeder, explained that the large impairment charge was related to Elixir based on “an update to estimate of lives for 2023 based on the latest selling season,” and that Rite Aid “expect[ed] lives to go down.” On this news, Rite Aid’s stock price fell by more than 28.02%, damaging investors. The Lead Plaintiff Process: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rite Aid securities during the Class Period to seek appointment as lead plaintiff in the Ride Aid class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rite Aid class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rite Aid class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rite Aid class action lawsuit.
Seeking Alpha • Oct 11Rite Aid partners with Google Cloud on pharmacy insights, customer engagementRite Aid (NYSE:RAD) has brokered a partnership with Google Cloud (NASDAQ:GOOG) that will provide the drug store chain with improved insights and customer experiences, as well as access to the Anthos platform for application deployment. Anthos will provide Rite Aid's (RAD) pharmacies with cloud computing capabilities on-site. In addition, it will support a vaccine scheduling tool, customer messaging infrastructure, and digital engagement platform. Rite Aid (RAD) will also benefit from Google Cloud's (GOOG) Retail Search product that provides customers with precise search results when shopping on the company's website. Also, Rite Aid (RAD) will migrate its enterprise data to Google Cloud (GOOG) using BigQuery which will provide improved insights into its finances, supply chain inventory, and customer information, powering data-driven decisions for its business operations. Check out why Seeking Alpha contributor WYCO Researcher rates Rite Aid (RAD) a hold.
Reported Earnings • Sep 30Second quarter 2023 earnings: EPS misses analyst expectationsSecond quarter 2023 results: US$6.07 loss per share (further deteriorated from US$1.86 loss in 2Q 2022). Revenue: US$5.90b (down 3.5% from 2Q 2022). Net loss: US$331.3m (loss widened 230% from 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to stay flat during the next 3 years compared to a 4.3% growth forecast for the Consumer Retailing industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.
お知らせ • Sep 30Rite Aid Corporation Announces Impairment Charges for the Second Quarter Ended August 27, 2022Rite Aid Corporation announced impairment charges for the second quarter ended August 27, 2022. For the quarter, the company reported goodwill and intangible asset impairment charges of $252,200,000.